Invention Grant
- Patent Title: Antisense compounds targeting Leucine-Rich repeat kinase 2(LRRK2) for the treatment of Parkinsons disease
-
Application No.: US16438015Application Date: 2019-06-11
-
Publication No.: US10787669B2Publication Date: 2020-09-29
- Inventor: Michelle L. Hastings , Ole Isacson , Joanna A. Korecka-Roet
- Applicant: Rosalind Franklin University of Medicine and Science , The McLean Hospital Corporation
- Applicant Address: US IL North Chicago US MA Belmont
- Assignee: Rosalind Franklin University of Medicine and Science,The McLean Hospital Corporation
- Current Assignee: Rosalind Franklin University of Medicine and Science,The McLean Hospital Corporation
- Current Assignee Address: US IL North Chicago US MA Belmont
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- Main IPC: C07H21/02
- IPC: C07H21/02 ; C07H21/04 ; C12N15/113
Abstract:
The present disclosure relates generally to compounds comprising oligonucleotides complementary to a Leucine-Rich-Repeat-Kinase (LRRK2) RNA transcript. Certain such compounds are useful for hybridizing to a LRRK2 RNA transcript, including but not limited to a LRRK2 RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRRK2 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Parkinson's disease.
Public/Granted literature
Information query
